These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38920307)

  • 1. Fecal and serum granulocyte protein levels in inflammatory bowel disease and irritable bowel syndrome and their relation to disease activity.
    Ekoff H; Rydell N; Hellström PM; Movérare R
    Clin Transl Gastroenterol; 2024 Jun; ():. PubMed ID: 38920307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease.
    Thorsvik S; Damås JK; Granlund AV; Flo TH; Bergh K; Østvik AE; Sandvik AK
    J Gastroenterol Hepatol; 2017 Jan; 32(1):128-135. PubMed ID: 27640344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
    Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
    J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
    Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis.
    Nielsen OH; Gionchetti P; Ainsworth M; Vainer B; Campieri M; Borregaard N; Kjeldsen L
    Am J Gastroenterol; 1999 Oct; 94(10):2923-8. PubMed ID: 10520846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
    Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
    Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Fecal Calprotectin with Different Endoscopic Scores in the Assessment of Ulcerative Colitis (UC) Activity and Its Utility in Differentiating IBS from IBD.
    Acharya K; Bhardwaj V; Chuahan I; Mushfiq S; Bhatt S; Lamba BM
    Euroasian J Hepatogastroenterol; 2023; 13(2):120-123. PubMed ID: 38222953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fecal neutrophil gelatinase-associated lipocalin is a surrogate marker of inflammation in inflammatory bowel disease].
    Zinkevich OD; Mukhametova DD; Abdulganieva DI; Safina NA; Koporulina MO; Odintsova AKh
    Eksp Klin Gastroenterol; 2014; (10):22-7. PubMed ID: 25911926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between fecal lactoferrin and inflammatory bowel disease.
    Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
    Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease.
    Ling Lundström M; Peterson C; Lampinen M; Hedin CRH; Keita ÅV; Kruse R; Magnusson MK; Lindqvist CM; Repsilber D; D'Amato M; Hjortswang H; Strid H; Rönnblom A; Söderholm JD; Öhman L; Venge P; Halfvarson J; Carlson M;
    Clin Transl Gastroenterol; 2023 Aug; 14(8):e00605. PubMed ID: 37256716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity.
    Yeşil A; Gönen C; Senateş E; Paker N; Gökden Y; Koçhan K; Erdem ED; Gündüz F
    Dig Dis Sci; 2013 Sep; 58(9):2587-93. PubMed ID: 23633156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn's disease.
    Budzynska A; Gawron-Kiszka M; Nowakowska-Dulawa E; Spiewak J; Lesinska M; Kukla M; Waluga M; Hartleb M
    J Physiol Pharmacol; 2017 Dec; 68(6):859-865. PubMed ID: 29550798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease.
    Jang HW; Kim HS; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Intest Res; 2016 Oct; 14(4):305-313. PubMed ID: 27799881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity.
    Menesy A; Hammad M; Aref S; Abozeid FAM
    BMC Gastroenterol; 2024 Apr; 24(1):135. PubMed ID: 38622545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Manolakis AC; Kapsoritakis AN; Georgoulias P; Tzavara C; Valotassiou V; Kapsoritaki A; Potamianos SP
    BMC Gastroenterol; 2010 Oct; 10():118. PubMed ID: 20946669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.